AR and prostate carcinoma: 1A). In recurrent patients with high AR expression (p = 0.023), there was a significant trend toward improved survival of those patients with high expression of CAMK2N1 (n = 19) compared to those with low CAMK2N1 expression (n = 20) in tumors (Figure. 1B). As revealed by IHC to determine the expression of AR and CAMK2N1 in the prostate cancer specimens (n=70) [8]. AR and CAMK2N1 were inversely correlated in human prostate cancer (r = −0.384, p = 0.0027) (Figure. 1C-D).